Edwards Lifesciences Corp (EW) Shares Sold by Optimum Investment Advisors

Optimum Investment Advisors lessened its stake in Edwards Lifesciences Corp (NYSE:EW) by 52.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 296 shares of the medical research company’s stock after selling 325 shares during the quarter. Optimum Investment Advisors’ holdings in Edwards Lifesciences were worth $45,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Regal Investment Advisors LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at $216,000. BB&T Securities LLC boosted its holdings in shares of Edwards Lifesciences by 0.9% during the fourth quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock valued at $1,252,000 after acquiring an additional 70 shares during the period. Securian Asset Management Inc boosted its holdings in shares of Edwards Lifesciences by 0.8% during the fourth quarter. Securian Asset Management Inc now owns 21,660 shares of the medical research company’s stock valued at $3,318,000 after acquiring an additional 164 shares during the period. Country Trust Bank boosted its holdings in shares of Edwards Lifesciences by 14.8% during the fourth quarter. Country Trust Bank now owns 184,751 shares of the medical research company’s stock valued at $28,298,000 after acquiring an additional 23,794 shares during the period. Finally, ETF Managers Group LLC boosted its holdings in shares of Edwards Lifesciences by 1,159.2% during the fourth quarter. ETF Managers Group LLC now owns 10,061 shares of the medical research company’s stock valued at $1,541,000 after acquiring an additional 9,262 shares during the period. Institutional investors and hedge funds own 87.15% of the company’s stock.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction dated Friday, December 21st. The shares were sold at an average price of $146.03, for a total value of $4,789,784.00. Following the completion of the sale, the chief executive officer now directly owns 75,926 shares of the company’s stock, valued at approximately $11,087,473.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $150.88, for a total transaction of $4,963,952.00. Following the completion of the sale, the chief executive officer now directly owns 76,026 shares of the company’s stock, valued at $11,470,802.88. The disclosure for this sale can be found here. Insiders sold 194,088 shares of company stock valued at $30,004,708 in the last ninety days. Corporate insiders own 1.84% of the company’s stock.

EW stock opened at $177.59 on Wednesday. The stock has a market capitalization of $36.20 billion, a P/E ratio of 37.79, a P/E/G ratio of 2.22 and a beta of 0.92. Edwards Lifesciences Corp has a fifty-two week low of $123.00 and a fifty-two week high of $178.39. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, hitting the consensus estimate of $1.17. The business had revenue of $977.70 million during the quarter, compared to the consensus estimate of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same quarter in the prior year, the company posted $0.94 earnings per share. On average, analysts anticipate that Edwards Lifesciences Corp will post 5.22 EPS for the current fiscal year.

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price target on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Monday, February 4th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $157.00 to $180.00 and gave the company an “overweight” rating in a report on Friday, December 7th. Canaccord Genuity boosted their price target on shares of Edwards Lifesciences from $177.00 to $186.00 and gave the company a “positive” rating in a report on Wednesday, January 16th. Finally, Raymond James boosted their price target on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “outperform” rating in a report on Thursday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $169.86.

ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2019/02/13/edwards-lifesciences-corp-ew-shares-sold-by-optimum-investment-advisors.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: What is an investor looking for in an SEC filing?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit